Allena Pharmaceuticals (ALNA) Stock Price, News & Analysis

Company Overview

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.02 to $0.16
• 52-Week Range: N/A
• Volume: 96,558 shs
• Average Volume: 15.69 million shs
• Market Capitalization: $37,000.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ALNA Stock Analysis - Frequently Asked Questions

How were Allena Pharmaceuticals' earnings last quarter?

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) announced its earnings results on Thursday, March, 31st. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.06.

When did Allena Pharmaceuticals IPO?

Allena Pharmaceuticals (ALNA) raised $80 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What other stocks do shareholders of Allena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Allena Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), TherapeuticsMD (TXMD), Sorrento Therapeutics (SRNE), Zomedica (ZOM).

Company Calendar

• Last Earnings: 3/31/2022
• Today: 1/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ALNA
• CUSIP: N/A
• CIK: 1624658
• Web: www.allenapharma.com
• Phone: (617) 467-4577
• Fax: 617-916-1871
• Employees: 35
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-48,660,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -287.46%
• Return on Assets: -146.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.58
• Quick Ratio: 1.58

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.23 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 122,083,000
• Free Float: 117,566,000
• Market Cap: $37,000.00
• Optionable: Not Optionable
• Beta: 1.13